Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Vasculitis

Risks and rewards of treating elderly patients with vasculitis

Antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis is a common cause of acute kidney injury in the elderly. This patient group is particularly susceptible to disease-related morbidity and mortality, and to adverse effects of induction immunosuppression. A new study adds to the debate on the most appropriate way to treat this vulnerable group of patients.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Moutzouris, D. A. et al. Renal biopsy in the very elderly. Clin. J. Am. Soc. Nephrol. 4, 1073–1082 (2009).

    CAS  Article  Google Scholar 

  2. 2

    Harper, L. & Savage, C. O. ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients. Rheumatology (Oxford) 44, 495–501 (2005).

    CAS  Article  Google Scholar 

  3. 3

    Chen, M., Yu, F., Zhang, Y. & Zhao, M. H. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore) 87, 203–209 (2008).

    CAS  Article  Google Scholar 

  4. 4

    Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036–1043 (2010).

    Article  Google Scholar 

  5. 5

    Flossman, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488–494 (2011).

    Article  Google Scholar 

  6. 6

    Mukhtyar, C. & Luqmani, R. Disease-specific quality indicators, guidelines, and outcome measures in vasculitis. Clin. Exp. Rheumatol. 25 (Suppl. 47), 120–129 (2007).

    CAS  PubMed  Google Scholar 

  7. 7

    Bomback, A. S. et al ANCA-associated glomerulonephritis in the very elderly. Kidney Int. doi:10.1038/ki.2010.489.

  8. 8

    de Groot, K. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670–680 (2009).

    Article  Google Scholar 

  9. 9

    Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).

    CAS  Article  Google Scholar 

  10. 10

    Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211–220 (2010).

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Charles D. Pusey.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tarzi, R., Pusey, C. Risks and rewards of treating elderly patients with vasculitis. Nat Rev Nephrol 7, 253–255 (2011). https://doi.org/10.1038/nrneph.2011.30

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing